Drugs / VNRX-9945
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04845321 | Jun → Oct 2021 | — | Venatorx Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VNRX-9945 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04845321 ↗ |
| Route | Oral | “Oral dosing” NCT04845321 ↗ |